Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Media 3 Undervalued Names Too Cheap to IgnoreReported by Nathan Reiff. Posted: 3/3/2026. Highly publicized growth stories from some of the largest companies may make 2026 seem like a poor time for a value strategy. Still, several sizable firms are trading at attractive valuations while also offering potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, with valuation metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits, including attractive dividends or promising new product developments. Value opportunities can be harder to find when many companies have regained investor attention, and some apparent bargains have deteriorating operations or other red flags. Fortunately, well-established, stable names can also present value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Although shares have climbed more than 28% in the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still has a price-to-earnings (P/E) ratio of 16.45, well below the medical industry average of close to 27. Analysts expect continued growth: the company is projected to see earnings climb by nearly 10% in the coming year and also has a predicted 5% of additional upside possible in the near term. What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO. Click here to get the details and I'll show you how to claim your stake… Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader challenges from the market.
- Merck's recent rally has not compromised its P/E ratio, which remains lower than the industry average, as the company navigates new ways to build revenue with its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases, with the former experiencing a sharp pullback and a high dividend yield and the latter rallying with adjusted EBITDA gains and the potential for further improvement in the future.
- Special Report: [Sponsorship-Ad-6-Format3]
Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which was approved for subcutaneous injection by the European Commission in late 2025 and reached about $8.4 billion in sales for Q4 2025, an increase of almost 7% year over year. Keytruda also shows promise for ovarian cancer treatments, potentially drawing interest from a new group of patients. These factors should help Merck build revenue as it prepares for Keytruda's patent exclusivity to end in 2028. Merck's drug portfolio is broadening: notable phase 3 trial results were recently announced for clesrovimab-cfor, marketed as Enflonsia, an RSV treatment for young children. At the same time, the company is restructuring—splitting its human health division into two units—to make it easier to expand non–cancer-drug sales as it navigates Keytruda's upcoming patent expiration. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) shares have fallen about 37% in the last year as the food-and-beverage staple has been pressured by tariffs and inflation. In Q1 fiscal 2026, which ended Nov. 2, 2025, the company reported modest year-over-year declines in organic net sales and consumption, with adjusted earnings per share (EPS) falling 13% over the same period. So far, margin improvement has been limited despite cost-saving measures. The near term is likely to remain challenging for the iconic brand, as guidance for the fiscal year is weak overall. However, improving supply-chain operations and strong brand loyalty—especially for its premium offerings—should help shield the company. Shifts in tariff policies may also reduce some of the pressure it faces. Campbell's remains an attractive dividend play, with an impressive yield of 5.99%, although its payout ratio is relatively high at more than 80%. Also notable: Campbell's P/E ratio of 13.50 is the lowest it has been in about four years. These factors may convince some investors that the stock is worth the risk, despite Wall Street caution. A Recent US Foods Rally May Continue as Bottom-Line Growth Remains in Place Foodservice distribution leader US Foods (NYSE: USFD) has taken a very different path from Campbell's—shares have climbed by about a third in the last year. Still, its P/E ratio, at 31.6, remains reasonable given the company's growth trajectory. On fundamentals, US Foods is making important strides: the company reported improving profitability in the latest quarter and posted full-year adjusted EBITDA gains of 11% year over year. Stronger inventory management and cost-of-goods savings are helping the firm gain traction. With a $4 billion capital-deployment plan in place, US Foods is positioning itself to maintain revenue momentum and continue the upward adjusted-EBITDA trend. Analysts rate USFD shares a Moderate Buy based on 11 Buys and 2 Holds, with roughly 15% upside potential.
| 
